EC Number   |
Application |
Reference |
|---|
   3.4.24.72 | drug development |
summary of results (including adverse events and pharmacodynamics) regarding drug development of alfimeprase as a potential drug against thrombosis and vascular disorders |
697595 |
| 3.4.24.72 | medicine |
development of more effective therapeutic approaches for treating occlusive thrombotic diseases, potential clinical interest in fibrolase for pharmacologic dissolution of an established thrombus |
649080 |
| 3.4.24.72 | medicine |
starase has the potential to be a potent thrombolytic agent due to its bi-functional properties (containing both direct-acting and plasminogen-activating activities) and lack of hemorrhagic activity |
733424 |
| 3.4.24.72 | medicine |
the enzyme effectively protects against acute pulmonary thromboembolism via degradation of thrombi with less activation of plasminogen |
718522 |
| 3.4.24.72 | medicine |
the enzyme has therapeutic potential in peptide-based cardiovascular drug development |
-, 733423 |
| 3.4.24.72 | medicine |
the enzyme is a candidate for antithrombotic drug development |
753870 |
| 3.4.24.72 | medicine |
the enzyme is used as thrombolytic drug |
-, 752419 |
| 3.4.24.72 | medicine |
the enzyme is useful for reducing or preventing thrombotic challenge |
752534 |
| 3.4.24.72 | medicine |
the use of the recombinant fibrolase alfimeprase results in rapid restoration of arterial patency in less than 4 h in most peripheral arterial occlusion patients |
721082 |
| 3.4.24.72 | medicine |
treatment of occlusive thrombi |
670960 |
